Welcome to our dedicated page for Caris Life Sciences SEC filings (Ticker: CAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Caris Life Sciences, Inc. filings document financial results, governance matters, financing arrangements and material company events for an AI TechBio precision medicine business. Form 8-K disclosures report quarterly and annual operating results, molecular profiling services revenue, clinical therapy selection activity, and Regulation FD updates tied to company presentations and diagnostic-development programs.
The company’s SEC record also includes a definitive proxy statement covering annual meeting proposals, director elections and auditor ratification. Other material-event filings describe senior secured credit facilities with subsidiary guarantees, amendments to bylaws affecting shareholder derivative proceedings, and capital-structure terms relevant to Caris’ public-company reporting obligations.
Vacirca Jeff L reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Jeff L. Vacirca received a grant of 13,192 shares of Common Stock on 2026-08-14, reported as an award of restricted stock units that vest under the applicable grant agreement. The award was recorded at $0.00 per share, and his direct holdings increased to 62,863 shares following the grant.
JOHANSEN LAURA I reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. reported that director Laura I. Johansen received a grant of 13,192 shares of Common Stock in the form of restricted stock units on 2026-08-14. The award was recorded at $0.00 per share and increased her directly held position to 343,897 shares. According to the accompanying note, these restricted stock units vest in accordance with the applicable grant agreement.
HALBERT JON reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. director Jon Halbert reported a grant of 13,192 restricted stock units of common stock on 2026-08-14 at $0.00 per share, vesting under an applicable grant agreement. Following this award, he holds 131,813 shares directly and indirect holdings of 652,062 shares through a family trust and 706,531 shares through LAH Investments, Ltd., where beneficial ownership is disclaimed except for his pecuniary interest.
Caris Life Sciences, Inc. received an updated passive ownership report from investment entities affiliated with J.H. Whitney. J.H. Whitney VI, L.P., together with J.H. Whitney Equity Partners VI, LLC, and managing members Paul R. Vigano and Robert M. Williams, Jr., report beneficial ownership of 11,256,615 shares of Caris common stock.
This position represents 4.0% of the outstanding common stock, with shared voting and dispositive power over all reported shares and no sole voting or dispositive power. The filing states that no other person has the right to receive, or direct the receipt of, dividends or sale proceeds from these securities. The amendment confirms that the reporting group now holds 5 percent or less of the class.
George H. Poste filed to sell common stock of CAI. A broker, Morgan Stanley Smith Barney LLC Executive Financial Services, is listed to handle the planned sale of 30,000 shares on 08/07/2026 on NASDAQ, with an aggregate value of $642,633.00.
The filing also notes a planned stock option exercise for 30,000 shares for cash on 08/07/2026, and discloses that 20,000 shares of common stock were sold on 08/03/2026 for $325,000.00 in the prior three months.
TSSP Sub-Fund HoldCo, LLC and Alan Waxman report updated ownership positions in Caris Life Sciences, Inc. common stock. As of June 30, 2026, they may be deemed to beneficially own 6,732,770 and 7,327,041 shares, respectively, reflecting 2.4% and 2.6% of the class based on 282,680,695 shares outstanding as of May 5, 2026. Both hold only shared voting and dispositive power over these shares through affiliated investment entities and disclaim beneficial ownership of securities held directly by those entities. They state that they no longer beneficially own more than five percent of the common stock, and this represents an exit reporting from five‑percent‑holder status.
Caris Life Sciences, Inc. reported higher results for the quarter ended June 30, 2026. Total revenue was 263,712 (amounts in thousands), up from 181,398 a year earlier, driven by molecular profiling services of 252,254, while pharma research and development services declined to 11,458.
Costs and operating expenses were 236,786, producing income from operations of 26,926 versus a prior-year operating loss of 17,989. A 25,232 loss on extinguishment of the 2023 term loan and interest expense of 9,228 led to a small net loss of 637 for the quarter and 1,147 year-to-date, compared with 71,790 and 174,370 in 2025.
As of June 30, 2026, Caris held cash, cash equivalents and restricted cash of 692,745 and short-term marketable securities of 102,200, against long-term indebtedness of 392,973. Operating activities provided 61,353 of cash in the first half. The company also authorized a 100.0 million share repurchase program and retired 1,000,000 shares for 17.9 million.
Caris Life Sciences, Inc. reported second quarter 2026 results and raised full-year 2026 revenue guidance to $1.03–$1.04 billion, representing growth of 27%–28% versus 2025.
For the quarter ended June 30, 2026, total revenue was $263.7 million, up 45% year over year, driven by 55% growth in molecular profiling services and approximately 59,200 clinical cases. Gross margin reached 68%, about 500 basis points higher than a year earlier. Net loss was $0.6 million, compared to $71.8 million in the prior-year quarter, and Adjusted EBITDA was $55.7 million.
Operating cash flow was $28.5 million and free cash flow $6.4 million. Cash, cash equivalents and restricted cash totaled 692,745 (amounts in thousands of dollars) at June 30, 2026. The company highlighted launches including Caris Detect and Caris ChromoSeq and a share repurchase program of up to $100 million, with approximately $82.1 million remaining authorized.
Caris Life Sciences director Jon Halbert reported an open-market purchase of 68,000 shares of Common Stock on May 15, 2026, at a weighted average price of $14.56 per share, through LAH Investments, Ltd.. These shares were bought in multiple trades between $14.49 and $14.60 per share. Following this transaction, LAH Investments, Ltd. held 704,598 shares indirectly, a family trust held 637,887 shares indirectly, and Halbert held 118,621 shares directly. Some indirect holdings include shares received in pro rata distributions exempt under Rule 16a-9, and Halbert disclaims beneficial ownership except to the extent of his pecuniary interest.